Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.
作者信息
Messa Emanuela, Gioia Daniela, Masiera Elisa, Castiglione Anna, Ceccarelli Manuela, Salvi Flavia, Danise Paolo, Sanna Alessandro, Allione Bernardino, Balleari Enrico, Poloni Antonella, Cametti Giovanni, Ferrero Dario, Tassara Rodolfo, Finelli Carlo, Bonferroni Margherita, Musto Pellegrino, Saglio Giuseppe, Levis Alessandro, Santini Valeria
机构信息
Division of Hematology, ASLTO 4, Ivrea (Turin).
Fondazione Italiana Sindromi Mielodisplastiche Onlus, Alessandria.
出版信息
Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3.
Abstract
摘要
相似文献
1
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.促红细胞生成素对国际预后评分系统低危/中危-1风险、无需输血的骨髓增生异常综合征患者总生存期的影响：一项队列研究
Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3.
2
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?体细胞突变能否预测低危骨髓增生异常综合征对促红细胞生成素刺激剂的反应？
Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7.
3
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?促红细胞生成素刺激剂的添加是否能改善用阿扎胞苷治疗的高危骨髓增生异常综合征的结局？
Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15.
4
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.促红细胞生成素在骨髓增生异常综合征中的实际应用：一项“罗马骨髓增生异常综合征研究组（GROM）”多中心研究
Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19.
5
Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.达贝泊汀α治疗低危或中危-1 风险骨髓增生异常综合征伴反应阳性预测因素的贫血。
Curr Med Res Opin. 2011 May;27(5):951-60. doi: 10.1185/03007995.2011.561834. Epub 2011 Mar 7.
6
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.芦可替尼治疗低危骨髓增生异常综合征相关贫血患者（PACE-MDS）：一项多中心、开放标签、2 期剂量发现研究和长期扩展研究。
Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.
7
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes.与骨髓增生异常综合征患者使用红细胞生成刺激剂相关的患者和医生特征。
Haematologica. 2012 Jan;97(1):128-32. doi: 10.3324/haematol.2011.049130.
8
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.促红细胞生成素刺激剂与骨髓增生异常综合征患者的血栓形成风险增加无关。
Haematologica. 2012 Jan;97(1):15-20. doi: 10.3324/haematol.2011.051755. Epub 2011 Nov 18.
9
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.阿扎胞苷对低危骨髓增生异常综合征及特定低危不良评分患者影响的多变量时间依赖性分析
Leuk Res. 2015 Jan;39(1):52-7. doi: 10.1016/j.leukres.2014.10.004. Epub 2014 Oct 30.
10
Darbepoetin alfa for anemia with myelodysplastic syndrome.聚乙二醇化促红细胞生成素α用于治疗骨髓增生异常综合征所致贫血
Expert Rev Hematol. 2015 Apr;8(2):139-46. doi: 10.1586/17474086.2015.1000854. Epub 2015 Jan 12.
引用本文的文献
1
How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome.如何在低危骨髓增生异常综合征中使用鲁索替尼和促红细胞生成剂。
Br J Haematol. 2025 Jul;207(1):15-26. doi: 10.1111/bjh.20126. Epub 2025 May 2.
2
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.在低危骨髓增生异常综合征（LR-MDS）的实际治疗中，对罗特西普的反应可以预测，并且能改善总生存期。
Hemasphere. 2025 Feb 12;9(2):e70086. doi: 10.1002/hem3.70086. eCollection 2025 Feb.
3
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.低危骨髓增生异常综合征患者使用促红细胞生成素后体细胞突变的结果及影响
Ther Adv Hematol. 2024 Jan 4;15:20406207231218157. doi: 10.1177/20406207231218157. eCollection 2024.
4
Practice review: Evidence-based and effective management of anaemia in palliative care patients.实践综述：姑息治疗患者贫血的循证有效管理。
Palliat Med. 2022 May;36(5):783-794. doi: 10.1177/02692163221081967. Epub 2022 Mar 24.
5
Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.低危骨髓增生异常综合征患者对红细胞生成刺激剂反应的预测。
Asian Pac J Cancer Prev. 2021 Dec 1;22(12):4037-4042. doi: 10.31557/APJCP.2021.22.12.4037.
6
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.不同剂量促红细胞生成素治疗骨髓增生异常综合征患者的效果：倾向评分匹配分析。
Cancer Med. 2019 Dec;8(18):7567-7576. doi: 10.1002/cam4.2638. Epub 2019 Oct 27.
本文引用的文献
1
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.一项评估低危 MDS 贫血患者使用促红细胞生成素-α的疗效和安全性的 3 期随机、安慰剂对照研究。
Leukemia. 2018 Dec;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9. Epub 2018 Mar 30.
2
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.一项关于聚乙二醇化促红细胞生成素α治疗贫血合并低危骨髓增生异常综合征患者的3期随机安慰剂对照试验。
Leukemia. 2017 Sep;31(9):1944-1950. doi: 10.1038/leu.2017.192. Epub 2017 Jun 19.
3
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.骨髓增生异常综合征，2.2017 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2017 Jan;15(1):60-87. doi: 10.6004/jnccn.2017.0007.
4
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?修订后的国际预后评分系统（IPSS）能否预测经典IPSS低危或中危-1骨髓增生异常综合征（MDS）患者对促红细胞生成素刺激剂的反应？
Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442.
5
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.成人原发性骨髓增生异常综合征的诊断和治疗：欧洲白血病网络的建议。
Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.
6
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.医保受益人群中骨髓增生异常综合征患者促红细胞生成素刺激剂的使用模式及其与临床指南的一致性。
Leuk Res. 2013 Jun;37(6):675-80. doi: 10.1016/j.leukres.2013.02.021. Epub 2013 Mar 21.
7
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.新的原发性骨髓增生异常综合征（MDS）和 MDS 衍生的少突细胞急性髓系白血病的综合细胞遗传学评分系统，源自国际数据库合并。
J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.
8
American society of clinical oncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.美国临床肿瘤学会/美国血液学会癌症成人患者使用促红细胞生成素和达贝泊汀临床实践指南更新。
J Oncol Pract. 2010 Nov;6(6):317-20. doi: 10.1200/JOP.2010.000132.
9
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.早期在低危 MDS 患者中引入 ESA 可能会延迟 RBC 输血的需求：对 112 例患者的回顾性分析。
Leuk Res. 2010 Nov;34(11):1430-6. doi: 10.1016/j.leukres.2010.05.030. Epub 2010 Jun 26.
10
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.骨髓增生异常综合征的临床管理：SIE、SIES、GITMO 实践指南更新。
Leuk Res. 2010 Dec;34(12):1576-88. doi: 10.1016/j.leukres.2010.01.018. Epub 2010 Feb 11.
Zotero 插件